Nitrendipine

CARDIOVASCULAR SYSTEM

Key facts

Nitrendipine is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1985. DrugCentral lists 19 molecular targets, including CACNA1C, CACNA1D and KCNN4.

• Molecular targets: CACNA1C, CACNA1D, KCNN4 and CYP2C9 (19 listed in DrugCentral).
• ATC code: C08CA08 (Dihydropyridine derivatives).
• Molecular formula: C18H20N2O6; molecular weight 360.37 g/mol.

Mechanism & targets

Molecular targets (19)

Target	Gene	Action	Activity
Voltage-dependent L-type calcium channel subunit alpha-1C	CACNA1C	blocker	Ki 9.60
Voltage-dependent L-type calcium channel subunit alpha-1D	CACNA1D	other	IC50 8.40
Intermediate conductance calcium-activated potassium channel protein 4	KCNN4	blocker	IC50 7.60
Cytochrome P450 2C9	CYP2C9	unknown	IC50 6.52
Voltage-dependent L-type calcium channel subunit alpha-1S	Cacna1s	other	IC50 6.00
Voltage-dependent L-type calcium channel subunit alpha-1F	CACNA1F	other	IC50 6.00
Voltage-dependent L-type calcium channel subunit alpha-1C	Cacna1c	other	IC50 6.00
Transthyretin	TTR	unknown	IC50 5.92
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	PDE1C	unknown	IC50 5.73
Cytochrome P450 2C19	CYP2C19	unknown	IC50 5.52
Adenosine receptor A3	ADORA3	unknown	Ki 5.08
Voltage-dependent T-type calcium channel subunit alpha-1H	CACNA1H	unknown	IC50 5.06
Adenosine receptor A1	Adora1	unknown	Ki 5.05
Potassium voltage-gated channel subfamily H member 2	KCNH2	unknown	IC50 5.00
ATP-binding cassette sub-family G member 2	ABCG2	unknown	IC50 4.68
Adenosine receptor A2a	Adora2a	unknown	Ki 4.64
Sodium channel alpha subunits; brain (Types I, II, III)	SCN1A|SCN2A|SCN3A	unknown	IC50 4.44
Platelet-activating factor receptor	PTAFR	unknown	Ki 4.13
Voltage-dependent calcium channel gamma-1 subunit	CACNG1	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1985-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
C08CA08	CARDIOVASCULAR SYSTEM › CALCIUM CHANNEL BLOCKERS › SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS › Dihydropyridine derivatives
C09BB06	CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, COMBINATIONS › ACE inhibitors and calcium channel blockers

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Product prescribing error	150.9
Renal cyst haemorrhage	126.4
General physical health deterioration	117.7
Delayed graft function	112.0
Syncope	101.4
Antinuclear antibody negative	101.2
Vena cava injury	98.1
Rectal prolapse	97.3
Abdominal wall haemorrhage	96.1
Vascular anastomotic haemorrhage	93.2
SARS-CoV-2 antibody test positive	92.0
Carotid arteriosclerosis	90.7

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Nitrendipine is on its molecule page.

• Molecular formula: C₁₈H₂₀N₂O₆
• Molecular weight: 360.37 g/mol
• CAS number: 39562-70-4
• InChIKey: PVHUJELLJLJGLN-UHFFFAOYSA-N
• PubChem CID: 4507

CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

How does Nitrendipine work?

Its molecular targets in DrugCentral include CACNA1C (blocker), CACNA1D, KCNN4 (blocker) and CYP2C9.

When was Nitrendipine first approved?

Nitrendipine was first approved by the YEAR INTRODUCED in 1985.

What is the chemical formula of Nitrendipine?

Nitrendipine has the molecular formula C18H20N2O6 and a molecular weight of 360.37 g/mol.

Sources

• DrugCentral drug card 1947 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL475534 — compound record and bioactivity
• PubChem CID 4507 — chemical identifiers
• DrugBank DB01054 — drug record
• FDA UNII 9B627AW319 — substance identity
• UniProt Q13936 (CACNA1C) — target protein
• UniProt Q01668 (CACNA1D) — target protein
• UniProt O15554 (KCNN4) — target protein
• UniProt P11712 (CYP2C9) — target protein
• UniProt O60840 (CACNA1F) — target protein
• UniProt P02766 (TTR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.